Rafarma Financial Statements From 2010 to 2024
| RAFA Stock | USD 0.06 0.01 8.96% |
Check Rafarma Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rafarma Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Rafarma financial statements analysis is a perfect complement when working with Rafarma Pharmaceuticals Valuation or Volatility modules.
Rafarma |
Rafarma Pharmaceuticals Company Return On Equity Analysis
Rafarma Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Rafarma Pharmaceuticals Return On Equity | -7.0E-4 |
Most of Rafarma Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rafarma Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Rafarma Pharmaceuticals has a Return On Equity of -7.0E-4. This is 100.0% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is 99.77% lower than that of the firm.
Rafarma Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Rafarma Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Rafarma Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rafarma Pharmaceuticals competition to find correlations between indicators driving Rafarma Pharmaceuticals's intrinsic value. More Info.Rafarma Pharmaceuticals is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Rafarma Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Rafarma Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Rafarma Pharmaceuticals Financial Statements
Rafarma Pharmaceuticals stakeholders use historical fundamental indicators, such as Rafarma Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Rafarma Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Rafarma Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Rafarma Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Rafarma Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. D. RAFARMA PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Rafarma Pink Sheet
Rafarma Pharmaceuticals financial ratios help investors to determine whether Rafarma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rafarma with respect to the benefits of owning Rafarma Pharmaceuticals security.